Werewolf Therapeutics (NASDAQ:HOWL) Trading 0.8% Higher - Still a Buy?

Key Points

• Werewolf Therapeutics' stock (NASDAQ:HOWL) saw a slight increase of 0.8% in trading, reaching a last price of $1.21, although there was a significant drop in trading volume by 56% from its average session.
• Analysts from Wedbush revised their price target for Werewolf Therapeutics, lowering it from $8.00 to $6.00 while maintaining an "outperform" rating.
• Institutional ownership in Werewolf Therapeutics stands at 64.84%, with significant increases in stakes from firms like Jane Street Group and Deutsche Bank AG in recent quarters.

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) shot up 0.8% during trading on Thursday . The stock traded as high as $1.28 and last traded at $1.21. 152,986 shares changed hands during mid-day trading, a decline of 56% from the average session volume of 344,749 shares. The stock had previously closed at $1.20.

Analyst Upgrades and Downgrades

Separately, Wedbush reduced their target price on Werewolf Therapeutics from $8.00 to $6.00 and set an "outperform" rating on the stock in a report on Friday, May 9th.

Werewolf Therapeutics Price Performance

The stock has a market capitalization of $52.05 million, a P/E ratio of -0.69 and a beta of 0.63. The business has a fifty day simple moving average of $1.24 and a 200-day simple moving average of $1.16. The company has a debt-to-equity ratio of 0.46, a quick ratio of 8.09 and a current ratio of 8.09.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.04. Sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Insider Activity

In other Werewolf Therapeutics news, Director Ra Capital Management, L.P. purchased 320,913 shares of the business's stock in a transaction on Monday, May 12th. The shares were purchased at an average cost of $0.86 per share, for a total transaction of $275,985.18. Following the acquisition, the director owned 6,021,969 shares of the company's stock, valued at approximately $5,178,893.34. This represents a 5.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 23.60% of the company's stock.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of institutional investors have recently modified their holdings of HOWL. Y Intercept Hong Kong Ltd acquired a new position in shares of Werewolf Therapeutics during the second quarter worth approximately $92,000. Deutsche Bank AG raised its position in shares of Werewolf Therapeutics by 450.7% during the fourth quarter. Deutsche Bank AG now owns 101,626 shares of the company's stock worth $150,000 after purchasing an additional 83,172 shares during the period. AQR Capital Management LLC acquired a new position in shares of Werewolf Therapeutics during the first quarter worth approximately $79,000. Nuveen LLC acquired a new position in shares of Werewolf Therapeutics during the first quarter worth approximately $71,000. Finally, JPMorgan Chase & Co. raised its position in shares of Werewolf Therapeutics by 372.4% during the fourth quarter. JPMorgan Chase & Co. now owns 62,928 shares of the company's stock worth $93,000 after purchasing an additional 49,608 shares during the period. 64.84% of the stock is owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.